Gyon Technologies Capital Management, LP Viridian Therapeutics, Inc.\De Transaction History

Gyon Technologies Capital Management, LP

4 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2022 Feb 13, 2023	SELL	$18.78 - $29.74 $34,048 - $53,918	-1,813 Reduced 18.31%	8,086 $236,000
Q3 2022 Nov 14, 2022	BUY	$10.7 - $25.5 $105,919 - $252,424	9,899 New	9,899 $203,000
Q2 2022 Aug 15, 2022	SELL	$9.55 - $19.0 $116,385 - $231,553	-12,187 Closed	0 $0
Q1 2022 May 12, 2022	BUY	$16.79 - $20.88 $204,619 - $254,464	12,187 New	12,187 $225,000

179

76.8M

581K

439K

Ticker VRDN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 39,888,900
Market Cap $806M
Description
Viridian Therapeutics, Inc., a biotechnology company, develops treatments for patients suffering from serious diseases. It develops VRDN-001, a humanized monoclonal anti-IGF-1R antibody that is in Phase 1/2 clinical trial for the treatment of thyroid eye disease (TED); VRDN-002, an IGF-1R antibody, which is in Phase 1 clinical trial; and VRDN-00...

Get notified when there are updates to the investment portfolio of Gyon Technologies Capital Management, LP, based on Form 13F filings with the SEC.

Stay updated on Gyon Technologies Capital Management, LP with notifications on news.